F-group (family)
2484.5.1.1 RVT_connect
Ligands and drugs
1,059
Member domains
549
with ligand contacts (≤ 4 Å)
51.8% of members
497
with DrugDomain annotations
46.9% of members
379
with a DrugBank compound
35.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2484.5.1.1 belongs to X-group 2484 Ribonuclease H-like, which binds 8.9 ligand superclasses per 20 proteins, broader than 77% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB08864 | T27 | Rilpivirine | 31 |
| DB00238 | NVP | Nevirapine | 29 |
| DB00625 | EFZ | Efavirenz | 11 |
| DB05871 | UC1 | UC-781 | 4 |
| DB06414 | 65B | Etravirine | 4 |
| DB07884 | HBQ | Opaviraline | 4 |
| DB07885 | HBY | Talviraline | 4 |
| DB08634 | TNK | 6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL | 3 |
| DB08665 | U05 | 6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE | 3 |
| DB12301 | 2KW | Doravirine | 3 |
| DB02721 | PYZ | 4-Iodopyrazole | 2 |
| DB07332 | AAP | ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE | 2 |
| DB07797 | FTC | N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA | 2 |
| DB08460 | R8E | MK-4965 | 2 |
| DB08598 | TB9 | R-82913 | 2 |
| DB08600 | TBO | Tivirapine | 2 |
| DB11649 | ZZE | Lersivirine | 2 |
| DB00705 | SPP | Delavirdine | 1 |
| DB01917 | PUT | Putrescine | 1 |
| DB06874 | 185 | (6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| T27 | 4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile | 31 |
| NVP | 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE | 28 |
| EFZ | (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE | 11 |
| K5C | 4-({4-[(4-{4-[(E)-2-cyanoethenyl]-2,6-dimethylphenoxy}thieno[3,2-d]pyrimidin-2-yl)amino]piperidin-1-yl}methyl)benzene-1-sulfonamide | 7 |
| MGmetal | MAGNESIUM ION | 6 |
| 29T | 8-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]phenoxy}indolizine-2-carbonitrile | 5 |
| 3LQ | 5-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]phenoxy}naphthalene-2-carbonitrile | 4 |
| 65B | 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE | 4 |
| 7N1 | 5-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]-4-fluorophenoxy}-7-fluoronaphthalene-2-carbonitrile | 4 |
| BYZ | 4-bromo-1H-pyrazole | 4 |
| FMQ | [1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]methanol | 4 |
| HBQ | ISOPROPYL (2S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDROQUINOXALINE-1(2H)-CARBOXYLATE | 4 |
| HBY | (S)-4-ISOPROPOXYCARBONYL-6-METHOXY-3-METHYLTHIOMETHYL-3,4-DIHYDROQUINOXALIN-2(1H)-THIONE | 4 |
| K5A | 4-[(4-{[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino}piperidin-1-yl)methyl]benzene-1-sulfonamide | 4 |
| UC1 | 2-METHYL-FURAN-3-CARBOTHIOIC ACID [4-CHLORO-3-(3-METHYL-BUT-2-ENYLOXY)-PHENYL]-AMIDE | 4 |
| 2KW | 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile | 3 |
| 3X6 | (2E)-3-(3-chloro-5-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]phenoxy}phenyl)prop-2-enenitrile | 3 |
| 494 | (2E)-3-(3-chloro-5-{4-chloro-2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]phenoxy}phenyl)prop-2-enenitrile | 3 |
| 9W3 | 4-[(4-{4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino}-6-[3-(morpholin-4-yl)propoxy]-1,3,5-triazin-2-yl)amino]benzonitrile | 3 |
| CL | CHLORIDE ION | 3 |